Design, Synthesis and Biological Evaluation of Novel Selective PI3Kδ Inhibitors Containing Pyridopyrimidine Scaffold

References

• Engelman JA , LuoJ , CantleyLC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet.7(8), 606–619 (2006).
   PubMed Web of Science ®Google Scholar
• Garces AE , StocksMJ. Class 1 PI3K clinical candidates and recent inhibitor design strategies: a medicinal chemistry perspective. J. Med. Chem.62(10), 4815–4850 (2018).
   PubMed Web of Science ®Google Scholar
• Cantley LC . The phosphoinositide 3-kinase pathway. Science296(5573), 1655–1657 (2002).
   PubMed Web of Science ®Google Scholar
• Durandy A , KrackerS. Increased activation of PI3 kinase-δ predisposes to B-cell lymphoma. Blood Am. J. Hematol.135(9), 638–643 (2020).
   Google Scholar
• Liu K , LiD , ZhengWet al. Discovery, optimization, and evaluation of quinazolinone derivatives with novel linkers as orally efficacious phosphoinositide-3-kinase delta inhibitors for treatment of inflammatory diseases. J. Med. Chem.64(13), 8951–8970 (2021).
   PubMed Web of Science ®Google Scholar
• Southworth T , PlumbJ , GuptaVet al. Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients. Respir.17(1), 1–12 (2016).
   Google Scholar
• Yang Q , ModiP , NewcombT , QuévaC , GandhiV. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin. Cancer Res.21(7), 1537–1542 (2015).
   PubMed Web of Science ®Google Scholar
• Vangapandu HV , JainN , GandhiV. Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia. Expert Opin. Investig. Drugs26(5), 625–632 (2017).
   PubMed Web of Science ®Google Scholar
• Burris HA , FlinnIW , PatelMRet al. Umbralisib, a novel PI3Kδ and casein kinase-1ϵ inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. Lancet Oncol.19(4), 486–496 (2018).
   PubMed Web of Science ®Google Scholar
• Hoegenauer K , SoldermannN , StaufferFet al. Discovery and pharmacological characterization of novel quinazoline-based PI3K delta-selective inhibitors. ACS Med. Chem. Lett.7(8), 762–767 (2016).
   PubMed Web of Science ®Google Scholar
• Hoegenauer K , SoldermannN , ZecriFet al. Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors. ACS Med. Chem. Lett.8(9), 975–980 (2017).
   PubMed Web of Science ®Google Scholar
• Perry M , AbdulaiR , MogemarkMet al. Evolution of PI3Kγ and δ inhibitors for inflammatory and autoimmune diseases. J. Med. Chem.62(10), 4783–4814 (2018).
   PubMed Web of Science ®Google Scholar
• Forero TA , RamchandrenR , YacoubAet al. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood133(16), 1742–1752 (2019).
   PubMed Web of Science ®Google Scholar
• Allen RA , BrookingsDC , PowellMJet al. Seletalisib: characterization of a novel, potent, and selective inhibitor of PI3Kδ. J. Pharmacol. Exp. Ther.361(3), 429–440 (2017).
   PubMed Web of Science ®Google Scholar
• Ino H , WilsonR , TeraoTet al. Evaluation of the safety, tolerability, and pharmacokinetics of GSK2269557 (nemiralisib) administered via dry powder inhaler to healthy Japanese subjects. Clin. Pharm. Drug Dev.8(1), 78–86 (2019).
   PubMed Web of Science ®Google Scholar
• Teng Y , LiX , RenSet al. Discovery of novel quinazoline derivatives as potent PI3Kδ inhibitors with high selectivity. Eur. J. Med. Chem.208, 112865 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang J , JiangH , LinSet al. Design and optimization of thienopyrimidine derivatives as potent and selective PI3Kδ inhibitors for the treatment of B-Cell malignancies. J. Med. Chem.65(11), 8011–8028 (2022).
   PubMed Web of Science ®Google Scholar
• Henley ZA , AmourA , BartonNet al. Optimization of orally bioavailable PI3Kδ inhibitors and identification of Vps34 as a key selectivity target. J. Med. Chem.63(2), 638–655 (2019).
   Web of Science ®Google Scholar
• Ma X , WeiJ , WangC , GuD , HuY , ShengR. Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies. Eur. J. Med. Chem.170, 112–125 (2019).
   PubMed Web of Science ®Google Scholar
• Li F , LiangX , JiangZet al. Discovery of (S)-2-(1-(4-amino-3-(3-fluoro-4-methoxyphenyl)-1 H-pyrazolo[3,4-d]pyrimidin-1-yl)propyl)-3-cyclopropyl-5-fluoroquinazolin-4(3H)-one (IHMT-PI3Kδ-372) as a potent and selective PI3Kδ inhibitor for the treatment of chronic obstructive pulmonary disease. J. Med. Chem.63(22), 13973–13993 (2020).
   PubMed Web of Science ®Google Scholar
• Shukla MR , PatraS , VermaMet al. Discovery of a potent and selective PI3Kδ inhibitor (S)-2, 4-diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with improved pharmacokinetic profile and superior efficacy in hematological cancer models. J. Med. Chem.63(23), 14700–14723 (2020).
   PubMed Web of Science ®Google Scholar
• Methot JL , ZhouH , McGowanMAet al. Projected dose optimization of amino-and hydroxypyrrolidine purine PI3Kδ immunomodulators. J. Med. Chem.64(8), 5137–5156 (2021).
   PubMed Web of Science ®Google Scholar
• Methot JL , ZhouH , KattarSDet al. Structure overhaul affords a potent purine PI3Kδ inhibitor with improved tolerability. J. Med. Chem.62(9), 4370–4382 (2019).
   PubMed Web of Science ®Google Scholar
• Amour A , BartonN , CooperAWJet al. Evolution of a novel, orally bioavailable series of PI3Kδ inhibitors from an inhaled lead for the treatment of respiratory disease. J. Med. Chem.59(15), 7239–7251 (2016).
   PubMed Web of Science ®Google Scholar
• Liu L , LiX , ChengYet al. Optimization of novel benzofuro[3,2-b]pyridin-2(1H)-one derivatives as dual inhibitors of BTK and PI3Kδ. Eur. J. Med. Chem.164, 304–316 (2019).
   PubMed Web of Science ®Google Scholar
• Yadav P , ShahK. Pyridopyrimidines as anticancer agents. ECS Trans.107(1), 11577 (2022).
   Google Scholar
• Buron F , MérourJY , AkssiraM , GuillaumetG , RoutierS. Recent advances in the chemistry and biology of pyridopyrimidines. Eur. J. Med. Chem.95, 76–95 (2015).
   PubMed Web of Science ®Google Scholar
• Ren Q , WangT , LiuJ , HeH. Progress in synthesis of pyridopyrimidine analogues. Chinese J. Org. Chem.25(12), 1530 (2005).
   Web of Science ®Google Scholar
• Hammouda MM , RashedMM , ElattarK , OsmanAM. Synthetic strategies of heterocycle-integrated pyridopyrimidine scaffolds supported by nano-catalysts. RSC Adv.13(17), 11600–11634 (2023).
   PubMed Web of Science ®Google Scholar
• Elattar KM , RabieR , HammoudaMM. Recent progress in the chemistry of bicyclic 6-6 systems: chemistry of pyrido[1,2-a]pyrimidines. Mon. Chem.148, 601–627 (2017).
   Web of Science ®Google Scholar
• Elattar KM , RabieR , HammoudaMM. Recent developments in the chemistry of bicyclic 6-6 systems: chemistry of pyrido[1,2-c]pyrimidines. Synth. Commun.46(18), 1477–1498 (2016).
   Web of Science ®Google Scholar
• Monier M , Abdel-LatifD , El-MekabatyA , MertB , ElattarK. Advances in the chemistry of 6-6 bicyclic systems: chemistry of pyrido[3,4-d]pyrimidines. Curr. Org. Synth.16(6), 812–854 (2019).
   PubMed Web of Science ®Google Scholar
• Xin M , DuanW , FengYet al. Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. Bioorg. Med. Chem.26(8), 2028–2040 (2018).
   PubMed Web of Science ®Google Scholar
• Xin M , DuanW , FengYet al. Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors. J. Enzym. Inhib. Med. Chem.33(1), 651–656 (2018).
   PubMed Web of Science ®Google Scholar
• Hei YY , XinM , ZhangH , XieX , MaoS , ZhangS. Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3Ks inhibitors. Bioorg. Med. Chem. Lett.26(18), 4408–4413 (2016).
   PubMed Web of Science ®Google Scholar
• Lei H , DuanW , ZhangSQet al. Discovery of potent and selective PI3Kδ inhibitors bearing amino acid fragments. Bioorg. Chem.138, 106594 (2023).
   PubMed Web of Science ®Google Scholar
• Feng Y , DuanW , FanS , ZhangH , ZhangS , XinM. Synthesis and biological evaluation of 4-(piperid-3-yl)amino substituted 6-pyridylquinazolines as potent PI3Kδ inhibitors. Bioorg. Med. Chem.27(19), 115035 (2019).
   PubMed Web of Science ®Google Scholar
• Lei H , FanS , ZhangHet al. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors, European Journal of Medicinal Chemistry. Eur. J. Med. Chem.186, 111888 (2020).
   PubMed Web of Science ®Google Scholar
• Zhao HY , YangXY , LeiHet al. Discovery of potent small molecule PROTACs targeting mutant EGFR. Eur. J. Med. Chem.208, 112781 (2020).
   PubMed Web of Science ®Google Scholar
• Hei YY , ZhangSQ , FengYet al. Alkylsulfonamide-containing quinazoline derivatives as potent and orally bioavailable PI3Ks inhibitors. Bioorg. Med. Chem.29(20), 114930 (2019).
   Google Scholar
• Lei H , ZhangSQ , BaiHet al. Discovery of novel, potent, and selective small-molecule Menin-Mixed Lineage Leukemia interaction inhibitors through attempting introduction of hydrophilic groups. J. Med. Chem.65(19), 13413–13435 (2022).
   PubMed Web of Science ®Google Scholar